While the federal spending bill passed at the end of 2022 will have a large impact on clinical labs, it doesn’t include LDTs reform.
Subscribe today for access to
Articles and Reports
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.
With temporary waivers of restriction relating to telehealth likely to end soon, here’s a roundup of the current state of state telehealth licensing law.
Though Congress didn’t pass VALID as part of the medical devices user fees bill, there’s still a good chance it will pass before year’s end.
It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.
After years of resistance, the lab industry’s hopes and prayers for relief from the flawed pricing scheme may soon be answered.
The most recent congressional effort to pass LDT legislation may prove to be the one that finally comes to fruition.
A briefing on how labs should prepare for the inevitable end of the PHE after more than two years of unprecedented relief.
The relief package agreed to on April 4 appears to have become a collateral victim of a politically incendiary issue regarding immigration.
Legislation would require Medicare to cover genomic cancer testing and follow-up screening for those with a family history of cancer.
The COVID-19 pandemic exposed the truth of something the lab industry has known and publicly stated repeatedly for over a decade: The FDA is ill-equipped to regulate Laboratory Developed Tests (LDTs) and allowing it to continue to do so, at least under its current...